CA-CYOLO
8.5.2024 14:31:36 CEST | Business Wire | Press release
Cyolo, the secure remote access company for operational technology (OT) and industrial control systems (ICS), today announced a strategic partnership with Dragos, a global leader in cybersecurity for ICS/OT. Under the umbrella of Cyolo’s CyoloVerse partner program, Cyolo's PRO Secure Remote Access Platform will work with Dragos’s industry-leading OT cybersecurity platform. This collaboration will provide organizations with a robust and interoperable solution to protect their critical infrastructure against cyber threats.
New technology implementations in ICS/OT environments pose unique risks for critical infrastructure. Today’s risks include lack of support for modern authentication or connectivity methods in traditional environments, connecting existing infrastructure with highly vulnerable end-of-life operating systems, or risk of breaches from third-party remote access.
This interoperability is designed to provide OT customers visibility and management of their asset inventory and enhance asset vulnerability detection and remediation capabilities through a seamless secure controlled access platform.
“Cyolo ICS/OT security and safety expertise are changing the way organizations understand secure remote access,” said Matt Cowell, VP of Business Development at Dragos. “With our companies’ complementary capabilities and unique strengths, we can manage security through the different layers of the operational environment and protect a wider array of organizations across critical infrastructure. Ultimately reducing risk as they expand connectivity.”
Bringing the Cyolo PRO platform alongside the Dragos OT-native network visibility and monitoring offerings gives an unparalleled advantage. The Dragos Platform enables organizations to scale protection, the threat intelligence to keep on top of current threats, and the tools to respond quickly to incidents. With Cyolo’s robust role-based access, application, and policy control, in the future the Dragos Platform will be able to manage Cyolo’s Identity-based parameters (users, applications, resources, policy) in accordance with SOC / IR policies and guidelines.
Together Cyolo and Dragos deliver a comprehensive ICS/OT security framework based on the five critical controls of effective ICS/OT security:
- ICS incident response—which integrates operational insights into incident handling, enhancing system integrity and recovery (Dragos)
- Defensible architecture—ensuring robust visibility, segmentation, and enforcement mechanisms to bridge technological and human aspects of security (Dragos and Cyolo PRO)
- ICS network visibility monitoring—employing continuous monitoring and protocol-aware tools to detect and address potential vulnerabilities (Dragos)
- Remote Access Security—ensuring safe and secure stringent access control in the face of evolving hybrid work environments (Cyolo PRO)
- Risk-based vulnerability management—prioritizing and addressing vulnerabilities based on their potential to pose significant operational risks, thereby ensuring proactive prevention, response, and recovery actions (Dragos and Cyolo PRO)
The solution plans to integrate Cyolo PRO and the Dragos Platform through an API architecture or operator console. It will deliver unsurpassed visibility and control of critical digital assets through secure identity-based access. Together, both companies will deliver simpler, stronger, and more efficient security controls that lay the foundation for Zero Trust (NIST 800-207).
“With this industry leading partnership, Cyolo joins Dragos to address security and operational challenges impacting OT environments," said Joe O’Donnell, EVP Corporate Development and OT GM at Cyolo. “The interoperability of the Dragos Platform and Cyolo PRO provides OT practitioners and industrial organizations with the full spectrum of cybersecurity services across the 5 ICS/OT Critical Controls. The timing could not be better as the world aggressively embraces Industry 4.0.”
Dino Busalachi, CTO and Co-Founder at Velta Technology - a joint partner - also highlighted that “In light of the surge in cyber threats, the growing adoption of Industry 4.0, and the inherent risks within OT environments, Velta Technology understands the critical need to partner with Cyolo and Dragos. Their joint solutions will provide our customers in the industrial sector with a tailored approach that strengthens their access security and elevates their overall security posture.”
Dragos and Cyolo respond to the need for secure industrial networks without disrupting operations, compromising safety or risking non-compliance.
The Dragos Platform offers the most effective industrial cybersecurity technology, giving customers visibility into their ICS/OT assets, vulnerabilities, threats, and response actions. The strength behind the Dragos Platform comes from Dragos’s ability to codify industry-leading OT threat intelligence, and insights from the Dragos services team into the software.
About Cyolo
Cyolo helps IT and ICS organizations stay secure and productive in an era of distributed workforces and unprecedented cyber threats. Cyolo’s platform enables all users, including employees, third parties, and remote or on-site workers, to connect to their working environments seamlessly and securely via modern identity-based authentication. With one unified solution that integrates with your existing tech stack, Cyolo makes securely connecting people to their work simple. To learn more, visit https://cyolo.io
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240508290964/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
